A randomized, multiple-dose, double blind, placebo controlled, parallel group, multicentric study to evaluate Efficacy and Safety of Beclomethasone Dipropionate Metered Dose Inhaler (Inhalation Aerosol) (0.04 mg/ INH) in male and/ or female subjects with Asthma [GroupI (Test): Beclomethasone Dipropionate 0.04 mg/ INH; Group II (Reference): QVARÂ® 40 mcg (Beclomethasone dipropionate HFA); and Group III: Placebo]

Aurobindo Pharma Research CenterII0 个研究点目标入组 1,550 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 1,550

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Adult male or female subjects of aged >=18 to <= 65 years inclusive.
•2. Diagnosis of asthma as defined by the National Asthma Education and Prevention Program at least 12 months prior to screening.
•3. Pre-bronchodilator FEV1 of >= 45% and <= 85% of predicted value during the screening visit and on the first day of treatment visit.
•4. >=15% and > 0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of Salbutamol inhalation (pMDI) on the first day of treatment visit.
•5. Subjects with FeNO > 25 ppb at screening and on the first day of treatment visit.
•6. Subjects stable on their chronic asthma treatment regimen for at least four weeks prior to enrollment.
•7. Subject should able to replace current SABAs with Salbutamol inhaler for use as needed for the duration of the study.
•8. Subject should be able to withhold all inhaled SABAs for at least six hours prior to lung function assessments on study visits.
•9. Ability to discontinue their asthma medications (inhaled corticosteroids and long-acting Î² agonists) during the run-in period and for remainder of the study.
•10. Asthma patients who are stable on low dose ICS or low dose ICS+LABA or who will be stable with low dose ICS as per Investigatorâ??s clinical judgement.
•11. Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having had <= 10 pack-years of historical use.
•12. Willingness to give their written informed consent to participate in the study.
•13. Subjects willing to perform all study related procedures including the use of study inhalers, Spirometry and willing to complete the Subject diary.
•14. Female of child-bearing potential, agreed to use a reliable method of contraception during study (e.g., condom + spermicide, IUD, oral, transdermal, injected or implanted hormonal contraceptives).

排除标准

•1. Life-threatening asthma, a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma related syncopal episode(s).
•2. Hospitalizations within the past year prior to the screening for the conditions mentioned in exclusion criteria No.01 or during the run-in period.
•3. Significant respiratory disease other than asthma (COPD, interstitial
•lung disease, etc.)
•4. Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension
•5. Evidence or history of clinically significant disease or abnormality including uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia.
•6. Historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the subject at risk through study participation, or would affect the study analyses if the disease exacerbates during the study.
•7. Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle ear infection within four weeks prior to the screening, during the run-in period, or on the day of treatment.
•8. Hypersensitivity to Beclomethasone or any of the ingredients of the formulation and any sympathomimetic drug (e.g., Salbutamol) or any inhaled, intranasal, or systemic corticosteroid therapy.
•9. Subjects receiving Î²2-blockers, anti-arrhythmics, anti-depressants, and monoamine oxidase inhibitors within 4 weeks prior to the screening.
•10. Subjects who required systemic corticosteroids (for any reason) within the past 2 months.
•11. Clinically significant abnormalities in ECG at screening as per investigators discretion.
•12. Female subjects who are pregnant, nursing or planning a pregnancy during the study.
•13. Subjects who have participated in another investigational drug or device research study within 30 days of screening.
•14. Subjects who are using any medication or has any disease which in the
•judgment of the Investigator will interfere with the conduct or interpretation of the study.

研究者

发起方

Aurobindo Pharma Research CenterII

相似试验

进行中（未招募）

不适用

EUCTR2010-020166-20-DEovartis Pharma Services AG48

进行中（未招募）

不适用

A randomized, double-blind, multiple-dose, placebo-controlled, parallel group study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of ACZ885 in patients with newly diagnosed type-1 diabetes mellitus (T1DM)Type-1 diabetes mellitusMedDRA version: 12.1Level: LLTClassification code 10067584Term: Type 1 diabetes mellitus

EUCTR2010-020166-20-GBovartis Pharma Services AG48

尚未招募

不适用

Compare the Efficacy and Safety of Budesonide andFormoterol Fumarate Dihydrate Inhalation Aerosol80/4.5 mcg per Actuation in Asthma patients

CTRI/2019/10/021627Deva Holding AS

进行中（未招募）

不适用

A Randomized, Multiple-dose, Double-Blind, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Study to determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat Inhaler in Patients with Chronic Obstructive PulmonaryDisease (COPD) -Chronic Obstructive Pulmonary Disease

EUCTR2005-000650-79-BEBoehringer Ingelheim Coordination Centre Belgium420

进行中（未招募）

1 期

A study to find out more about the effect of AMG 181 in people with moderate to severe ulcerative colitisMedDRA version: 16.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856Moderate to severe Ulcerative Colitis

EUCTR2011-005251-13-LVAmgen Inc360